BioCentury
ARTICLE | Clinical News

Omni Bio Pharmaceutical preclinical data

April 8, 2013 7:00 AM UTC

In a mouse model of gouty arthritis, Fc-AAT dose-dependently reduced joint swelling, IL-6 and IL-1 beta levels, and cell influx vs. IV immunoglobulin (IVIG), with a significant reduction in joint swelling at the 50 µg Fc-AAT dose (p<0.001). Omni Bio said that the 50 µg dose of Fc-AAT was at least as effective as a 10 mg dose of Kineret anakinra. Fc-AAT is a recombinant fusion protein consisting of the Fc domain of human IgG1 attached to alpha 1-antitrypsin (AAT; A1AT; SERPINA1). Data were presented at the European Workshop on Crystals in Human Diseases meeting in Paris. Next year, the company plans to submit an IND to FDA to begin a Phase Ib/IIa trial of Fc-AAT. ...